IL233463B - Chimeric factor viii polypeptides and uses thereof - Google Patents
Chimeric factor viii polypeptides and uses thereofInfo
- Publication number
- IL233463B IL233463B IL233463A IL23346314A IL233463B IL 233463 B IL233463 B IL 233463B IL 233463 A IL233463 A IL 233463A IL 23346314 A IL23346314 A IL 23346314A IL 233463 B IL233463 B IL 233463B
- Authority
- IL
- Israel
- Prior art keywords
- factor viii
- chimeric factor
- viii polypeptides
- polypeptides
- chimeric
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261586099P | 2012-01-12 | 2012-01-12 | |
| US201261586654P | 2012-01-13 | 2012-01-13 | |
| US201261667901P | 2012-07-03 | 2012-07-03 | |
| US201261734954P | 2012-12-07 | 2012-12-07 | |
| PCT/US2013/021330 WO2013106787A1 (en) | 2012-01-12 | 2013-01-12 | Chimeric factor viii polypeptides and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL233463A0 IL233463A0 (en) | 2014-08-31 |
| IL233463B true IL233463B (en) | 2020-03-31 |
Family
ID=48781968
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL233463A IL233463B (en) | 2012-01-12 | 2014-06-30 | Chimeric factor viii polypeptides and uses thereof |
| IL261632A IL261632B (en) | 2012-01-12 | 2018-09-05 | Chimeric factor viii polypeptides and uses thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL261632A IL261632B (en) | 2012-01-12 | 2018-09-05 | Chimeric factor viii polypeptides and uses thereof |
Country Status (29)
| Country | Link |
|---|---|
| US (3) | US11370827B2 (enExample) |
| EP (3) | EP3505179B1 (enExample) |
| JP (4) | JP6255630B2 (enExample) |
| KR (1) | KR102212098B1 (enExample) |
| CN (4) | CN109111526A (enExample) |
| AU (2) | AU2016202875B2 (enExample) |
| BR (1) | BR112014017165B1 (enExample) |
| CA (1) | CA2863328A1 (enExample) |
| CO (1) | CO7010788A2 (enExample) |
| CY (1) | CY1122509T1 (enExample) |
| DK (1) | DK2804623T3 (enExample) |
| EA (2) | EA028309B1 (enExample) |
| ES (2) | ES3073593T3 (enExample) |
| HR (1) | HRP20191920T1 (enExample) |
| HU (1) | HUE046396T2 (enExample) |
| IL (2) | IL233463B (enExample) |
| LT (1) | LT2804623T (enExample) |
| MX (1) | MX357403B (enExample) |
| MY (1) | MY201293A (enExample) |
| NZ (1) | NZ626945A (enExample) |
| PH (2) | PH12014501602B1 (enExample) |
| PL (1) | PL2804623T3 (enExample) |
| PT (1) | PT2804623T (enExample) |
| RS (1) | RS59670B1 (enExample) |
| SG (2) | SG11201403764XA (enExample) |
| SI (1) | SI2804623T1 (enExample) |
| TW (3) | TWI826778B (enExample) |
| WO (1) | WO2013106787A1 (enExample) |
| ZA (1) | ZA201405094B (enExample) |
Families Citing this family (78)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006063031A2 (en) | 2004-12-06 | 2006-06-15 | Haplomics | Allelic variants of human factor viii |
| EP2865760B1 (en) | 2008-06-24 | 2017-10-11 | CSL Behring GmbH | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| HRP20191920T1 (hr) | 2012-01-12 | 2020-01-10 | Bioverativ Therapeutics Inc. | Kimerni polipeptidi faktora viii i njihova uporaba |
| CN111548418A (zh) | 2012-02-15 | 2020-08-18 | 比奥贝拉蒂治疗公司 | 因子viii组合物及其制备和使用方法 |
| WO2013123457A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| AU2013270683A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Chimeric clotting factors |
| AU2013270682A1 (en) | 2012-06-08 | 2014-12-11 | Biogen Ma Inc. | Procoagulant compounds |
| US10023628B2 (en) | 2012-07-06 | 2018-07-17 | Bioverativ Therapeutics Inc. | Cell line expressing single chain factor VIII polypeptides and uses thereof |
| ES2770501T3 (es) | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc | Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos |
| US10272163B2 (en) | 2012-12-07 | 2019-04-30 | The Regents Of The University Of California | Factor VIII mutation repair and tolerance induction |
| RS61387B2 (sr) | 2013-02-15 | 2024-06-28 | Bioverativ Therapeutics Inc | Gen optimizovanog faktora viii |
| SG11201505926VA (en) | 2013-03-15 | 2015-09-29 | Biogen Ma Inc | Factor ix polypeptide formulations |
| EP2796145B1 (en) * | 2013-04-22 | 2017-11-01 | CSL Ltd. | A covalent complex of von willebrand factor and faktor viii linked by a disulphide bridge |
| HK1223303A1 (zh) * | 2013-06-28 | 2017-07-28 | Bioverativ Therapeutics Inc. | 凝血酶可裂解连接子 |
| KR20230007555A (ko) * | 2013-06-28 | 2023-01-12 | 바이오버라티브 테라퓨틱스 인크. | Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 |
| EP3875106A1 (en) * | 2013-08-08 | 2021-09-08 | Bioverativ Therapeutics Inc. | Purification of chimeric fviii molecules |
| US10548953B2 (en) | 2013-08-14 | 2020-02-04 | Bioverativ Therapeutics Inc. | Factor VIII-XTEN fusions and uses thereof |
| US10611794B2 (en) | 2013-09-25 | 2020-04-07 | Bioverativ Therapeutics Inc. | On-column viral inactivation methods |
| EA201691111A1 (ru) | 2014-01-10 | 2017-01-30 | Байоджен Ма Инк. | Химерные белки фактора viii и их применение |
| US11008561B2 (en) | 2014-06-30 | 2021-05-18 | Bioverativ Therapeutics Inc. | Optimized factor IX gene |
| DK3164150T3 (da) * | 2014-07-02 | 2021-02-08 | CSL Behring Lengnau AG | Modificeret von willebrand-faktor |
| US10626164B2 (en) | 2014-07-25 | 2020-04-21 | Csl Limited | Purification of VWF |
| KR102554850B1 (ko) * | 2015-02-06 | 2023-07-13 | 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 | 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도 |
| CA2986626A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Truncated von willebrand factor polypeptides for treating hemophilia |
| CA2986625A1 (en) | 2015-05-22 | 2016-12-01 | Csl Behring Recombinant Facility Ag | Methods for preparing modified von willebrand factor |
| UA126016C2 (uk) * | 2015-08-03 | 2022-08-03 | Біовератів Терапеутікс Інк. | Злитий білок фактора іх |
| EP3334452A4 (en) * | 2015-08-12 | 2019-04-17 | Cell Machines, Inc. | METHOD AND COMPOSITIONS IN CONJUNCTION WITH COMBUSTION COMPLEXES WITH LONG HALF TIME |
| US10143760B2 (en) | 2015-10-28 | 2018-12-04 | Sangamo Therapeutics, Inc. | Liver-specific constructs, factor VIII expression cassettes and methods of use thereof |
| CN108884145B (zh) * | 2015-11-13 | 2023-08-22 | 武田药品工业株式会社 | 用于血友病a的基因治疗的具有增加的表达的编码重组fviii变体的病毒载体 |
| WO2017112895A1 (en) * | 2015-12-23 | 2017-06-29 | Haplomics, Inc. | F8 gene repair |
| AU2017204955B2 (en) | 2016-01-07 | 2021-04-01 | CSL Behring Lengnau AG | Mutated truncated von Willebrand Factor |
| KR20180118659A (ko) | 2016-02-01 | 2018-10-31 | 바이오버라티브 테라퓨틱스 인크. | 최적화된 viii 인자 유전자 |
| DK3417058T3 (da) * | 2016-02-16 | 2021-11-15 | Res Found Dev | Sortase-modificerede molekyler og anvendelser deraf |
| US12171808B2 (en) * | 2016-05-20 | 2024-12-24 | Octapharma Ag | Glycosylated VWF fusion proteins with improved pharmacokinetics |
| JP6877469B2 (ja) * | 2016-06-24 | 2021-05-26 | モガム・インスティテュート・フォー・バイオメディカル・リサーチＭｏｇａｍ Ｉｎｓｔｉｔｕｔｅ Ｆｏｒ Ｂｉｏｍｅｄｉｃａｌ Ｒｅｓｅａｒｃｈ | Ｆｖｉｉｉおよびｖｗｆ因子を含むキメラタンパク質、ならびにそれらの使用 |
| KR102219859B1 (ko) * | 2016-06-24 | 2021-02-25 | 재단법인 목암생명과학연구소 | 재조합 단쇄 fviii 및 그 화학 접합물 |
| US10738338B2 (en) | 2016-10-18 | 2020-08-11 | The Research Foundation for the State University | Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate |
| JP2020504082A (ja) | 2016-11-11 | 2020-02-06 | ツェー・エス・エル・ベーリング・レングナウ・アクチエンゲゼルシャフト | 血液凝固障害の処置又は予防における血管外投与のための切断型フォン・ヴィルブランド因子ポリペプチド |
| DK3538133T3 (da) | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili |
| CA3044838A1 (en) | 2016-12-02 | 2018-06-07 | Bioverativ Therapeutics Inc. | Methods of inducing immune tolerance to clotting factors |
| KR20190090827A (ko) | 2016-12-02 | 2019-08-02 | 바이오버라티브 테라퓨틱스 인크. | 키메라 응고 인자를 사용해 혈우병성 관절증을 치료하는 방법 |
| JP7244428B2 (ja) * | 2017-02-27 | 2023-03-22 | シャタック ラボ，インコーポレイテッド | Ｖｓｉｇ８ベースのキメラタンパク質 |
| DK3641800T5 (da) | 2017-06-22 | 2024-08-26 | CSL Behring Lengnau AG | Modulation af fviii immunogenicitet ved trunkeret vwf |
| MX2020001593A (es) | 2017-08-09 | 2020-07-13 | Bioverativ Therapeutics Inc | Moleculas de acido nucleico y usos de las mismas. |
| US20210038744A1 (en) | 2018-02-01 | 2021-02-11 | Bioverativ Therapeutics Inc. | Use of lentiviral vectors expressing factor viii |
| CN117467019A (zh) * | 2018-05-18 | 2024-01-30 | 郑州晟斯生物科技有限公司 | 改进的fviii融合蛋白及其应用 |
| KR102914074B1 (ko) | 2018-05-18 | 2026-01-16 | 바이오버라티브 테라퓨틱스 인크. | A형 혈우병의 치료 방법 |
| CN113166271A (zh) * | 2018-05-18 | 2021-07-23 | 郑州晟斯生物科技有限公司 | 具有延长半衰期的融合多肽缀合物 |
| WO2020006576A1 (en) * | 2018-06-29 | 2020-01-02 | City Of Hope | Compositions and methods for treating autoimmune diseases |
| US12091675B2 (en) | 2018-07-16 | 2024-09-17 | Takeda Pharmaceutical Company Limited | Gene therapy of hemophilia a using viral vectors encoding recombinant FVIII variants with increased expression |
| AU2019314513B2 (en) | 2018-08-03 | 2026-04-30 | Sangamo Therapeutics, Inc. | Improved clinical parameters by expression of factor viii |
| JP7602454B2 (ja) | 2018-08-09 | 2024-12-18 | バイオベラティブ セラピューティクス インコーポレイテッド | 核酸分子及び非ウイルス遺伝子治療のためのそれらの使用 |
| JP7604376B2 (ja) | 2018-12-28 | 2024-12-23 | バーテックス ファーマシューティカルズ インコーポレイテッド | 改変ウロキナーゼ型プラスミノゲンアクティベータポリペプチドおよび使用方法 |
| TWI851647B (zh) | 2019-01-16 | 2024-08-11 | 日商武田藥品工業股份有限公司 | 用於a型血友病基因治療之編碼表現增加之重組fviii變異體的病毒載體 |
| US10654911B1 (en) * | 2019-04-02 | 2020-05-19 | Beijing Neoletix Biological Technology Co., Ltd. | Vector co-expressing truncated von Willebrand factor and factor VIII |
| EP3736286A1 (en) | 2019-05-09 | 2020-11-11 | Biotest AG | Single chain factor viii molecule |
| CN112175088B (zh) * | 2019-07-02 | 2023-03-28 | 江苏晟斯生物制药有限公司 | 改进的fix融合蛋白、缀合物及其应用 |
| WO2021001522A1 (en) | 2019-07-04 | 2021-01-07 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
| AU2020342349A1 (en) * | 2019-09-02 | 2022-03-03 | Biotest Ag | Factor VIII protein with increased half-life |
| EP3785726A1 (en) * | 2019-09-02 | 2021-03-03 | Biotest AG | Factor viii protein with increased half-life |
| JP7803014B2 (ja) | 2019-09-30 | 2026-01-21 | バイオベラティブ セラピューティクス インコーポレイテッド | レンチウイルスベクター製剤 |
| WO2021094344A1 (en) | 2019-11-11 | 2021-05-20 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
| KR102865175B1 (ko) | 2019-12-19 | 2025-09-30 | 악스톤 바이오사이언시스 코퍼레이션 | 초-장기 작용 인슐린-fc 융합 단백질 및 사용 방법 |
| WO2021165226A1 (en) * | 2020-02-17 | 2021-08-26 | Biotest Ag | Subcutaneous administration of factor viii |
| JP2023537565A (ja) | 2020-06-24 | 2023-09-04 | バイオベラティブ セラピューティクス インコーポレイテッド | タンパク質を発現するように改変されたレンチウイルスベクターの調製物から遊離第ｖｉｉｉ因子を除去する方法 |
| CN113087803B (zh) * | 2021-05-12 | 2022-10-14 | 苏州大学附属第一医院 | 抗人血管性血友病因子前导肽单克隆抗体sz176及其应用 |
| US20250154216A1 (en) * | 2022-02-16 | 2025-05-15 | University Of Miami | Il-2 and tl1a fusion proteins and methods of use thereof |
| JP2024053226A (ja) * | 2022-10-03 | 2024-04-15 | 株式会社三洋物産 | 遊技機 |
| JP2024053229A (ja) * | 2022-10-03 | 2024-04-15 | 株式会社三洋物産 | 遊技機 |
| JP2024053221A (ja) * | 2022-10-03 | 2024-04-15 | 株式会社三洋物産 | 遊技機 |
| JP2024053228A (ja) * | 2022-10-03 | 2024-04-15 | 株式会社三洋物産 | 遊技機 |
| JP2024053230A (ja) * | 2022-10-03 | 2024-04-15 | 株式会社三洋物産 | 遊技機 |
| JP2024053223A (ja) * | 2022-10-03 | 2024-04-15 | 株式会社三洋物産 | 遊技機 |
| JP2024053227A (ja) * | 2022-10-03 | 2024-04-15 | 株式会社三洋物産 | 遊技機 |
| JP2024053222A (ja) * | 2022-10-03 | 2024-04-15 | 株式会社三洋物産 | 遊技機 |
| JP2024053224A (ja) * | 2022-10-03 | 2024-04-15 | 株式会社三洋物産 | 遊技機 |
| CN120757663B (zh) * | 2025-07-04 | 2025-12-30 | 广州至善生物科技发展有限公司 | 一种神经干细胞及其在修复脊髓损伤中的应用 |
Family Cites Families (164)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4215051A (en) | 1979-08-29 | 1980-07-29 | Standard Oil Company (Indiana) | Formation, purification and recovery of phthalic anhydride |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4757006A (en) | 1983-10-28 | 1988-07-12 | Genetics Institute, Inc. | Human factor VIII:C gene and recombinant methods for production |
| US4965199A (en) | 1984-04-20 | 1990-10-23 | Genentech, Inc. | Preparation of functional human factor VIII in mammalian cells using methotrexate based selection |
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| US4965188A (en) | 1986-08-22 | 1990-10-23 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US5981216A (en) | 1985-04-01 | 1999-11-09 | Alusuisse Holdings A.G. | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| MX9203440A (es) | 1985-04-12 | 1992-07-01 | Genetics Inst | Proteinas procoagulantes novedosas. |
| KR910006424B1 (ko) | 1985-08-21 | 1991-08-24 | 인코텍스 비.브이 | 편성브리프(brief) 제조방법 |
| ATE87663T1 (de) | 1986-01-03 | 1993-04-15 | Genetics Inst | Verfahren zur herstellung von faktor-viii:c-typ- proteinen. |
| US5595886A (en) | 1986-01-27 | 1997-01-21 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| US5422260A (en) * | 1986-05-29 | 1995-06-06 | Genetics Institute, Inc. -Legal Affairs | Human factor VIII:c muteins |
| US5543502A (en) | 1986-06-24 | 1996-08-06 | Novo Nordisk A/S | Process for producing a coagulation active complex of factor VIII fragments |
| US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
| JP3101690B2 (ja) | 1987-03-18 | 2000-10-23 | エス・ビィ・２・インコーポレイテッド | 変性抗体の、または変性抗体に関する改良 |
| CA1331157C (en) | 1987-04-06 | 1994-08-02 | Randal J. Kaufman | Method for producing factor viii:c-type proteins |
| US6060447A (en) | 1987-05-19 | 2000-05-09 | Chiron Corporation | Protein complexes having Factor VIII:C activity and production thereof |
| IE69026B1 (en) | 1987-06-12 | 1996-08-07 | Immuno Ag | Novel proteins with factor VIII activity process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| US6346513B1 (en) | 1987-06-12 | 2002-02-12 | Baxter Trading Gmbh | Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them |
| DE3720246A1 (de) | 1987-06-19 | 1988-12-29 | Behringwerke Ag | Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet |
| FR2619314B1 (fr) | 1987-08-11 | 1990-06-15 | Transgene Sa | Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant |
| US4994371A (en) | 1987-08-28 | 1991-02-19 | Davie Earl W | DNA preparation of Christmas factor and use of DNA sequences |
| JPS6461751A (en) | 1987-09-01 | 1989-03-08 | Konishiroku Photo Ind | Silver halide photographic sensitive material |
| US6780613B1 (en) | 1988-10-28 | 2004-08-24 | Genentech, Inc. | Growth hormone variants |
| US5004803A (en) | 1988-11-14 | 1991-04-02 | Genetics Institute, Inc. | Production of procoagulant proteins |
| US5053337A (en) | 1989-10-30 | 1991-10-01 | Neurogenetic Corporation | DNA encoding an α2B -adrenergic receptor |
| SE465222C5 (sv) | 1989-12-15 | 1998-02-10 | Pharmacia & Upjohn Ab | Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning |
| US5846951A (en) | 1991-06-06 | 1998-12-08 | The School Of Pharmacy, University Of London | Pharmaceutical compositions |
| IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
| US5364771A (en) | 1992-04-07 | 1994-11-15 | Emory University | Hybrid human/porcine factor VIII |
| US5859204A (en) | 1992-04-07 | 1999-01-12 | Emory University | Modified factor VIII |
| US6376463B1 (en) | 1992-04-07 | 2002-04-23 | Emory University | Modified factor VIII |
| US6037452A (en) | 1992-04-10 | 2000-03-14 | Alpha Therapeutic Corporation | Poly(alkylene oxide)-Factor VIII or Factor IX conjugate |
| US5563045A (en) | 1992-11-13 | 1996-10-08 | Genetics Institute, Inc. | Chimeric procoagulant proteins |
| SE504074C2 (sv) | 1993-07-05 | 1996-11-04 | Pharmacia Ab | Proteinberedning för subkutan, intramuskulär eller intradermal administrering |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| GB9422383D0 (en) | 1994-11-05 | 1995-01-04 | Wellcome Found | Antibodies |
| US6818439B1 (en) | 1994-12-30 | 2004-11-16 | Chiron Corporation | Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders |
| US6030613A (en) | 1995-01-17 | 2000-02-29 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6485726B1 (en) | 1995-01-17 | 2002-11-26 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of therapeutics |
| US6086875A (en) | 1995-01-17 | 2000-07-11 | The Brigham And Women's Hospital, Inc. | Receptor specific transepithelial transport of immunogens |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| US6458563B1 (en) | 1996-06-26 | 2002-10-01 | Emory University | Modified factor VIII |
| AU3968897A (en) | 1996-08-02 | 1998-02-25 | Bristol-Myers Squibb Company | A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis |
| WO1998023289A1 (en) | 1996-11-27 | 1998-06-04 | The General Hospital Corporation | MODULATION OF IgG BINDING TO FcRn |
| US20020019036A1 (en) * | 1996-12-13 | 2002-02-14 | Hans-Peter Schwarz | Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor |
| US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| GB9809951D0 (en) | 1998-05-08 | 1998-07-08 | Univ Cambridge Tech | Binding molecules |
| JP2002522063A (ja) | 1998-08-17 | 2002-07-23 | アブジェニックス インコーポレイテッド | 増加した血清半減期を有する改変された分子の生成 |
| US6927044B2 (en) | 1998-09-25 | 2005-08-09 | Regeneron Pharmaceuticals, Inc. | IL-1 receptor based cytokine traps |
| EP1006183A1 (en) | 1998-12-03 | 2000-06-07 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Recombinant soluble Fc receptors |
| US6358703B1 (en) | 1998-12-10 | 2002-03-19 | Bayer Corporation | Expression system for factor VIII |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
| US7829085B2 (en) * | 1999-07-14 | 2010-11-09 | Life Sciences Research Partners Vzw | Methods of treating hemostasis disorders using antibodies binding the C1 domain of factor VIII |
| US6926898B2 (en) | 2000-04-12 | 2005-08-09 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2001258536A1 (en) | 2000-05-16 | 2001-11-26 | Lipoxen Technologies Limited | Derivatisation of proteins in aqueous solution |
| GB0029407D0 (en) | 2000-12-01 | 2001-01-17 | Affitech As | Product |
| EP1355919B1 (en) | 2000-12-12 | 2010-11-24 | MedImmune, LLC | Molecules with extended half-lives, compositions and uses thereof |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| US20040106794A1 (en) | 2001-04-16 | 2004-06-03 | Schering Corporation | 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands |
| CA2450125A1 (en) * | 2001-06-15 | 2002-12-27 | Andre C. Schuh | Gene therapy for hemophilia a |
| CA2841097A1 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin and g-csf fusion proteins |
| KR101271635B1 (ko) | 2001-12-21 | 2013-06-12 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 알부민 융합 단백질 |
| US20080194481A1 (en) | 2001-12-21 | 2008-08-14 | Human Genome Sciences, Inc. | Albumin Fusion Proteins |
| US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
| US20040132101A1 (en) | 2002-09-27 | 2004-07-08 | Xencor | Optimized Fc variants and methods for their generation |
| US7317091B2 (en) | 2002-03-01 | 2008-01-08 | Xencor, Inc. | Optimized Fc variants |
| US20040018557A1 (en) | 2002-03-01 | 2004-01-29 | Immunomedics, Inc. | Bispecific antibody point mutations for enhancing rate of clearance |
| CA2479212A1 (en) | 2002-03-15 | 2003-09-25 | Brigham And Women's Hospital, Inc. | Central airway administration for systemic delivery of therapeutics |
| PT1534335E (pt) | 2002-08-14 | 2012-02-28 | Macrogenics Inc | Anticorpos específicos de fcγriib e processos para a sua utilização |
| AU2003275103A1 (en) | 2002-09-17 | 2004-04-08 | Diffusion Science, Inc. | Electrochemical generation, storage and reaction of hydrogen and oxygen using gas permeable catalyst-coated hollow microspheres |
| CA2832136C (en) | 2002-09-27 | 2015-11-17 | Xencor | Optimized fc variants and methods for their generation |
| ATE480562T1 (de) | 2002-10-15 | 2010-09-15 | Facet Biotech Corp | Veränderung von fcrn-bindungsaffinitäten oder von serumhalbwertszeiten von antikörpern mittels mutagenese |
| GB2395337B (en) | 2002-11-14 | 2005-12-28 | Gary Michael Wilson | Warning Unit |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| US7041635B2 (en) | 2003-01-28 | 2006-05-09 | In2Gen Co., Ltd. | Factor VIII polypeptide |
| EP1596887B1 (en) * | 2003-02-26 | 2022-03-23 | Nektar Therapeutics | Polymer-factor viii moiety conjugates |
| KR100851263B1 (ko) | 2003-02-28 | 2008-08-08 | 가부시키가이샤 구라레 | 경화성 수지 조성물 |
| US20090010920A1 (en) | 2003-03-03 | 2009-01-08 | Xencor, Inc. | Fc Variants Having Decreased Affinity for FcyRIIb |
| US8388955B2 (en) | 2003-03-03 | 2013-03-05 | Xencor, Inc. | Fc variants |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| SI1624891T2 (sl) | 2003-05-06 | 2013-09-30 | Biogen Idec Hemophilia Inc. | Strjevalni faktor-FC himerni proteini za zdravljenje hemofilije |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| EP1654290B1 (en) | 2003-08-12 | 2019-03-13 | Lipoxen Technologies Limited | Sialic acid derivatives for protein derivatisation and conjugation |
| GB0324368D0 (en) | 2003-10-17 | 2003-11-19 | Univ Cambridge Tech | Polypeptides including modified constant regions |
| US7211559B2 (en) | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
| WO2005047327A2 (en) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO |
| EP1697520A2 (en) | 2003-12-22 | 2006-09-06 | Xencor, Inc. | Fc polypeptides with novel fc ligand binding sites |
| JP4762156B2 (ja) | 2004-01-12 | 2011-08-31 | アプライド モレキュラー エボリューション，インコーポレイテッド | Ｆｃ領域変異体 |
| US7276585B2 (en) | 2004-03-24 | 2007-10-02 | Xencor, Inc. | Immunoglobulin variants outside the Fc region |
| WO2005123780A2 (en) | 2004-04-09 | 2005-12-29 | Protein Design Labs, Inc. | Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis |
| WO2006085967A2 (en) | 2004-07-09 | 2006-08-17 | Xencor, Inc. | OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS |
| EP3342782B1 (en) | 2004-07-15 | 2022-08-17 | Xencor, Inc. | Optimized fc variants |
| US7566701B2 (en) | 2004-09-07 | 2009-07-28 | Archemix Corp. | Aptamers to von Willebrand Factor and their use as thrombotic disease therapeutics |
| WO2006047350A2 (en) | 2004-10-21 | 2006-05-04 | Xencor, Inc. | IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION |
| AU2005322067B8 (en) | 2004-12-27 | 2012-07-26 | Takeda Pharmaceutical Company Limited | Polymer-von Willebrand factor-conjugates |
| CA2618476A1 (en) | 2005-08-12 | 2007-02-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7846445B2 (en) | 2005-09-27 | 2010-12-07 | Amunix Operating, Inc. | Methods for production of unstructured recombinant polymers and uses thereof |
| US7855279B2 (en) * | 2005-09-27 | 2010-12-21 | Amunix Operating, Inc. | Unstructured recombinant polymers and uses thereof |
| CA2644712C (en) * | 2006-03-06 | 2016-09-13 | Amunix, Inc. | Unstructured recombinant polymers and uses thereof |
| KR20090019770A (ko) | 2006-03-13 | 2009-02-25 | 티아이알 테크놀로지 엘피 | 고상 조명 시스템용 적응형 제어 장치 및 전압 결정 방법 |
| CN101415445A (zh) | 2006-03-31 | 2009-04-22 | 巴克斯特国际公司 | 聚乙二醇化的因子ⅷ |
| WO2007144173A1 (en) | 2006-06-14 | 2007-12-21 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| EP1867660A1 (en) * | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| CN101516388B (zh) * | 2006-07-21 | 2012-10-31 | 诺和诺德公司 | 通过o-联糖基化序列的肽的糖基化 |
| WO2008033413A2 (en) | 2006-09-14 | 2008-03-20 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US8969532B2 (en) | 2006-10-03 | 2015-03-03 | Novo Nordisk A/S | Methods for the purification of polypeptide conjugates comprising polyalkylene oxide using hydrophobic interaction chromatography |
| WO2008060780A2 (en) | 2006-10-04 | 2008-05-22 | Novo Nordisk A/S | Glycerol linked pegylated sugars and glycopeptides |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| EP1935430A1 (en) * | 2006-12-22 | 2008-06-25 | CSL Behring GmbH | Modified coagulation factors with prolonged in vivo half-life |
| RU2571931C2 (ru) * | 2007-04-13 | 2015-12-27 | Каталист Биосайенсис, Инк. | Полипептиды на основе модифицированного фактора vii и их применение |
| EP2162535A4 (en) | 2007-06-04 | 2011-02-23 | Novo Nordisk As | O-linked glycosylation using N-acetylglucosamine transferases |
| US8563521B2 (en) | 2007-06-21 | 2013-10-22 | Technische Universitat Munchen | Biological active proteins having increased in vivo and/or in vitro stability |
| CA2695374A1 (en) * | 2007-08-15 | 2009-02-19 | Amunix, Inc. | Compositions and methods for modifying properties of biologically active polypeptides |
| CA2703948A1 (en) * | 2007-11-01 | 2009-05-07 | University Of Rochester | Recombinant factor viii having increased stability |
| AU2008323768A1 (en) | 2007-11-09 | 2009-05-14 | Baxter Healthcare S.A. | Modified recombinant Factor VIII and von Willebrand Factor and methods of use |
| EP2244814B1 (en) | 2007-12-28 | 2021-06-02 | Takeda Pharmaceutical Company Limited | Recombinant vwf formulations |
| ES2298096B1 (es) | 2008-01-08 | 2009-01-01 | Grifols, S.A. | Procedimiento para la obtencion de un concentrado de factor von willebrand o del complejo de factor viii/factor von willebrand y utilizacionde los mismos. |
| EP2865760B1 (en) * | 2008-06-24 | 2017-10-11 | CSL Behring GmbH | Factor viii, von willebrand factor or complexes thereof with prolonged in vivo half-life |
| DE102008032361A1 (de) | 2008-07-10 | 2010-01-21 | Csl Behring Gmbh | Der Einsatz von Faktor VIII und vWF bzw. vWF-enthaltenden Konzentraten zur Therapie der durch Thrombocyten-Inhibitoren induzierte Koagulopathie |
| PL2604693T3 (pl) | 2008-07-21 | 2016-09-30 | Jednołańcuchowe cząsteczki TNFSF | |
| EP2368124A4 (en) | 2008-11-24 | 2012-09-19 | Bayer Healthcare Llc | METHOD FOR DETERMINING THE ACTIVITY OF A PEGYLATED BLOOD GENERATION FACTOR IN A SILICON-BASED ACTIVATED PART THROMBOPLASTINE TIME ASSAY |
| US8703717B2 (en) | 2009-02-03 | 2014-04-22 | Amunix Operating Inc. | Growth hormone polypeptides and methods of making and using same |
| US8680050B2 (en) | 2009-02-03 | 2014-03-25 | Amunix Operating Inc. | Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same |
| DK3178835T3 (da) | 2009-02-03 | 2019-06-24 | Amunix Pharmaceuticals Inc | Forlængede rekombinante polypeptider og sammensætninger omfattende samme |
| EP2411024A4 (en) * | 2009-03-24 | 2013-02-27 | Bayer Healthcare Llc | Variants of factor viii and associated methods of use |
| JP2012523438A (ja) | 2009-04-10 | 2012-10-04 | タフツ メディカル センター インコーポレイテッド | メタロプロテイナーゼ−１（ｍｍｐ−１）によるｐａｒ−１活性化 |
| PE20121539A1 (es) | 2009-06-08 | 2012-12-06 | Amunix Operating Inc | Polipeptidos de la hormona de crecimiento y metodos de preparacion |
| WO2010144508A1 (en) | 2009-06-08 | 2010-12-16 | Amunix Operating Inc. | Glucose-regulating polypeptides and methods of making and using same |
| EP2467166A2 (en) | 2009-08-20 | 2012-06-27 | CSL Behring GmbH | Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders |
| CA2771999A1 (en) | 2009-08-24 | 2011-03-10 | Amunix Operating Inc. | Coagulation factor vii compositions and methods of making and using same |
| WO2011028344A2 (en) | 2009-08-25 | 2011-03-10 | Amunix Operating Inc. | Interleukin-1 receptor antagonist compositions and methods of making and using same |
| RU2579977C2 (ru) * | 2009-11-13 | 2016-04-10 | Грифольс Терапьютикс Инк. | СОДЕРЖАЩИЕ ФАКТОР ФОН ВИЛЛЕБРАНДА (vWF) ПРЕПАРАТЫ И СПОСОБЫ, НАБОРЫ И ПРИМЕНЕНИЯ, СВЯЗАННЫЕ С НИМИ |
| EP4382170A3 (en) * | 2009-12-06 | 2024-09-04 | Bioverativ Therapeutics Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| WO2011101284A1 (en) | 2010-02-16 | 2011-08-25 | Novo Nordisk A/S | Factor viii fusion protein |
| EP2536753B1 (en) * | 2010-02-16 | 2017-12-20 | Novo Nordisk A/S | Factor viii molecules with reduced vwf binding |
| WO2011123830A2 (en) | 2010-04-02 | 2011-10-06 | Amunix Operating Inc. | Alpha 1-antitrypsin compositions and methods of making and using same |
| BR112012029666A2 (pt) | 2010-05-20 | 2020-10-06 | Allergan, Inc. | toxinas clostridiais degradáveis |
| US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
| PT2591006T (pt) | 2010-07-09 | 2019-07-29 | Bioverativ Therapeutics Inc | Moléculas de cadeia simples processáveis e polipéptidos preparados utilizando as mesmas |
| US20130017997A1 (en) | 2010-08-19 | 2013-01-17 | Amunix Operating Inc. | Factor VIII Compositions and Methods of Making and Using Same |
| HRP20191920T1 (hr) | 2012-01-12 | 2020-01-10 | Bioverativ Therapeutics Inc. | Kimerni polipeptidi faktora viii i njihova uporaba |
| CN111548418A (zh) | 2012-02-15 | 2020-08-18 | 比奥贝拉蒂治疗公司 | 因子viii组合物及其制备和使用方法 |
| WO2013123457A1 (en) | 2012-02-15 | 2013-08-22 | Biogen Idec Ma Inc. | Recombinant factor viii proteins |
| ES2770501T3 (es) * | 2012-07-11 | 2020-07-01 | Bioverativ Therapeutics Inc | Complejo del factor VIII con XTEN y proteína del factor de Von Willebrand y sus usos |
| KR20230007555A (ko) | 2013-06-28 | 2023-01-12 | 바이오버라티브 테라퓨틱스 인크. | Xten을 지닌 트롬빈 절단가능한 링커 및 이의 용도 |
| HK1223303A1 (zh) | 2013-06-28 | 2017-07-28 | Bioverativ Therapeutics Inc. | 凝血酶可裂解连接子 |
| EA201691111A1 (ru) | 2014-01-10 | 2017-01-30 | Байоджен Ма Инк. | Химерные белки фактора viii и их применение |
| KR102914074B1 (ko) * | 2018-05-18 | 2026-01-16 | 바이오버라티브 테라퓨틱스 인크. | A형 혈우병의 치료 방법 |
-
2013
- 2013-01-12 HR HRP20191920TT patent/HRP20191920T1/hr unknown
- 2013-01-12 ES ES18211179T patent/ES3073593T3/es active Active
- 2013-01-12 JP JP2014552353A patent/JP6255630B2/ja active Active
- 2013-01-12 EP EP18211179.9A patent/EP3505179B1/en active Active
- 2013-01-12 HU HUE13735649A patent/HUE046396T2/hu unknown
- 2013-01-12 PL PL13735649T patent/PL2804623T3/pl unknown
- 2013-01-12 DK DK13735649T patent/DK2804623T3/da active
- 2013-01-12 WO PCT/US2013/021330 patent/WO2013106787A1/en not_active Ceased
- 2013-01-12 CN CN201810666645.7A patent/CN109111526A/zh active Pending
- 2013-01-12 LT LT13735649T patent/LT2804623T/lt unknown
- 2013-01-12 SI SI201331602T patent/SI2804623T1/sl unknown
- 2013-01-12 PT PT137356499T patent/PT2804623T/pt unknown
- 2013-01-12 SG SG11201403764XA patent/SG11201403764XA/en unknown
- 2013-01-12 MX MX2014008512A patent/MX357403B/es active IP Right Grant
- 2013-01-12 BR BR112014017165-3A patent/BR112014017165B1/pt active IP Right Grant
- 2013-01-12 EP EP13735649.9A patent/EP2804623B1/en active Active
- 2013-01-12 CN CN201911267518.0A patent/CN111499761A/zh active Pending
- 2013-01-12 ES ES13735649T patent/ES2753124T3/es active Active
- 2013-01-12 KR KR1020147022369A patent/KR102212098B1/ko active Active
- 2013-01-12 CN CN201380013452.7A patent/CN104271150A/zh active Pending
- 2013-01-12 US US14/371,948 patent/US11370827B2/en active Active
- 2013-01-12 CA CA2863328A patent/CA2863328A1/en active Pending
- 2013-01-12 MY MYPI2018001814A patent/MY201293A/en unknown
- 2013-01-12 EA EA201491186A patent/EA028309B1/ru not_active IP Right Cessation
- 2013-01-12 RS RS20191424A patent/RS59670B1/sr unknown
- 2013-01-12 CN CN201911266598.8A patent/CN111499760A/zh active Pending
- 2013-01-12 NZ NZ626945A patent/NZ626945A/en unknown
- 2013-01-12 EA EA201791134A patent/EA035323B1/ru unknown
- 2013-01-12 EP EP26167836.1A patent/EP4775263A2/en active Pending
- 2013-01-12 SG SG10201610193RA patent/SG10201610193RA/en unknown
- 2013-01-14 TW TW110112317A patent/TWI826778B/zh active
- 2013-01-14 TW TW107124686A patent/TWI727187B/zh active
- 2013-01-14 TW TW102101337A patent/TW201348253A/zh unknown
-
2014
- 2014-06-30 IL IL233463A patent/IL233463B/en active IP Right Grant
- 2014-07-11 PH PH12014501602A patent/PH12014501602B1/en unknown
- 2014-07-11 ZA ZA2014/05094A patent/ZA201405094B/en unknown
- 2014-07-15 CO CO14152717A patent/CO7010788A2/es unknown
-
2016
- 2016-05-04 AU AU2016202875A patent/AU2016202875B2/en active Active
-
2017
- 2017-11-15 JP JP2017219879A patent/JP6728121B2/ja active Active
-
2018
- 2018-02-16 AU AU2018201163A patent/AU2018201163B2/en active Active
- 2018-06-13 PH PH12018501250A patent/PH12018501250A1/en unknown
- 2018-09-05 IL IL261632A patent/IL261632B/en unknown
-
2019
- 2019-11-07 CY CY20191101171T patent/CY1122509T1/el unknown
-
2020
- 2020-02-26 JP JP2020030737A patent/JP7113860B2/ja active Active
-
2022
- 2022-05-27 US US17/826,932 patent/US20230011438A1/en active Pending
- 2022-07-26 JP JP2022118552A patent/JP7475613B2/ja active Active
-
2025
- 2025-11-21 US US19/397,119 patent/US20260193320A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL261632B (en) | Chimeric factor viii polypeptides and uses thereof | |
| EP2839019A4 (en) | CD3 BINDING POLYPEPTIDES | |
| EP2940135A4 (en) | HETERODIMIZED POLYPEPTIDE | |
| DK2970441T3 (da) | AGLYCOSYLEREDE Fc-INDEHOLDENDE POLYPEPTIDER | |
| IL241085B (en) | Hyperglycosylated binding polypeptides | |
| DK2920197T3 (da) | Prolinlåste sammenhæftede peptider og anvendelser deraf | |
| SG11201602889TA (en) | Novel polypeptides | |
| ZA201500097B (en) | Modified factor x polypeptides and uses thereof | |
| PL2863942T3 (pl) | Cząstki sprzężone z peptydem | |
| SG11201505924TA (en) | Factor viii polypeptide formulations | |
| FI20116212L (fi) | Polypeptidi | |
| CL2014002180A1 (es) | Peptidos antomicrobianos | |
| ZA201407276B (en) | Polypeptides and their use | |
| DK3572090T3 (da) | Korttidsvirkende faktor-vii-polypeptider | |
| FR2986233B1 (fr) | Peptide bifonctionnel | |
| IL236690B (en) | Ube2t peptides and vaccines containing the same | |
| EP2920206A4 (en) | MODIFIED APOL1 POLYPEPTIDE | |
| DK2861241T3 (da) | Forbedrede cd31-peptider | |
| ZA201504462B (en) | TGFß-DERIVED POLYPEPTIDES AND USES THEREOF | |
| FI20126394L (fi) | Tiivistyselementti ja -järjestely | |
| FR3014440B1 (fr) | Polypeptides entomotoxiques | |
| EP2937362A4 (en) | RECOMBINANT PROTEIN | |
| GB201318941D0 (en) | Novel polypeptides |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |